HomeAI · summaries
Storia in 5 fonti
FDA approves Trutakna for proteinuria reduction in IgA nephropathy
The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to an agency press release. Atacicept-vymj (Trutakna, Vera Therapeutics) is the first approved medication to target both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in immunoglobulin A (IgA)
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Trutakna for proteinuria reduction in IgA nephropathy
The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to…
- ·
medpagetoday.com
First-in-Class Drug Approved for IgA Nephropathy
It has not been established whether atacicept slows kidney function decline long-term, however
